non targeting control pool  (MedChemExpress)

Journal: Cell Death & Disease

Article Title: Caspase-2 protects against ferroptotic cell death

doi: 10.1038/s41419-024-06560-6

Figure Lengend Snippet: a Immunoblot analysis of caspase-2 and p53 expression in H1299 Parental p53 null , H1299 p53 R273H , and mut-p53 Flo-1 cells 48 h after transfection with control or CASP2 siRNA. Vinculin is shown as the loading control. Mean IC50 values after 72 h treatment with b erastin, c SAS, d RSL3 and e BSO in H1299 Parental p53 null , H1299p53 R273H and mut- p53 Flo-1 with control or CASP2 siRNA. f Viability of H1299p53 R273H cells with control and CASP2 siRNA at 72 h post-treatment with 1 μM erastin, alone or in combination with ferrostatin-1 (Fer-1, 20 μM), deferoxamine (DFO, 100 μM), Trolox (Tro, 1 mM), β- mercaptoethanol (β-mer, 100 μM), N-acetylcysteine (NAC, 5 mM), glutathione-methylethyl ester (GSH-MEE, 5 mM) or QVD (25 μM). b – f Data represented as mean ± s.e.m. from three or four independent experiments. Unpaired t -test and one-way ANOVA with Dunnett’s post hoc test were used to estimate significant differences in b – e and f , respectively. In f , comparisons were made between erastin only vs. cotreatment with ferroptosis inhibitors group in CASP2 siRNA cells. P -values are indicated with ns (not significant), * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: Cells were transfected with 40 nM Casp2 (ON-TARGET plus Human CASP2 siRNA SMARTpool L-003465-00-0050), Casp3 (ON-TARGET plus Human CASP3 siRNA SMARTpool L-004307-00-0020) or non-targeting control siRNA pools (ON-TARGET plus non-targeting pool D-001810-10-05) using Lipofectamine RNAiMAX transfection reagent (Life Technologies) as per the manufacturer’s instructions.

Techniques: Western Blot, Expressing, Transfection

Journal: Cell Death & Disease

Article Title: Caspase-2 protects against ferroptotic cell death

doi: 10.1038/s41419-024-06560-6

Figure Lengend Snippet: Volcano plots illustrating DEGs in a H1299p53 R273H cells transfected with CASP2 siRNA vs. control siRNA and b CASP2 −/− vs. Cas9 H1299p53 R273H cells. Red dots indicate DEGs with nominal P -value < 0.05 and log2FC > or < –1. The top 10 (based on log2 FC) upregulated and downregulated DEGs are labeled. c Venn diagram of unique and overlapping DEGs ( P -value < 0.05) in CASP2 siRNA vs. control siRNA group and CASP2 −/− vs. Cas9 group. d Heat-map displaying common up/downregulated genes with log2FC > 1 or < -1. e GO term analysis of the significantly enriched biological processes (nominal P -value < 0.01) in common DEGs in the absence of caspase-2 using Metascape .

Article Snippet: Cells were transfected with 40 nM Casp2 (ON-TARGET plus Human CASP2 siRNA SMARTpool L-003465-00-0050), Casp3 (ON-TARGET plus Human CASP3 siRNA SMARTpool L-004307-00-0020) or non-targeting control siRNA pools (ON-TARGET plus non-targeting pool D-001810-10-05) using Lipofectamine RNAiMAX transfection reagent (Life Technologies) as per the manufacturer’s instructions.

Techniques: Transfection, Labeling

Journal: Cell Reports Medicine

Article Title: An activity-based functional test for identifying homologous recombination deficiencies across cancer types in real time

doi: 10.1016/j.xcrm.2023.101247

Figure Lengend Snippet:

Article Snippet: siRNA non-targeting pool control , GE Dharmacon , Cat# D-001810-10-20.

Techniques: Virus, Derivative Assay, Recombinant, Purification, Cell Isolation, Sequencing, Software

Journal: Toxicology Reports

Article Title: Dasatinib targets c-Src kinase in cardiotoxicity

doi: 10.1016/j.toxrep.2023.04.013

Figure Lengend Snippet: The role of c-Src in regulation of cardiomyocyte viability A-B. Neonatal rat cardiomyocytes were transfected with control siRNA, 10 nM of c-Src siRNA or 30 nM of c-Src siRNA as indicated in the figure. A. Shown is Western blot analysis for c-Src and GAPDH. B. Shown is analysis for cardiomyocyte viability by ATP assay and analysis for cell death by measuring the release of adenylate kinase 5 days after transfection (N = 4). *p < 0.05, * *p < 0.01 vs control siRNA. Statistics were calculated by one-way analysis of variance followed by Dunnett’s post hoc test. C. Cardiomyocytes were transfected with control siRNA, 25 nM of c-Src siRNA or 80 nM of c-Src siRNA as indicated. Cell death was monitored by adenylate kinase assay 4, 5 and 6 days after transfection. Data are shown as relative to adenylate kinase release from control siRNA treated cells at 4 days after transfection. * *p < 0.01 vs control siRNA; #p < 0.05 vs 25 nM c-Src siRNA. Statistics were calculated by repeated measures ANOVA.

Article Snippet: Specific Src siRNA (ThermoFisher ID s136282) and negative control siRNA (ThermoFisher/Dharmacon siGENOME Non-Targeting siRNA Control Pool D-001206–13–50) were transfected into cardiomyocytes using Lipofectamine2000 as a transfection reagent.

Techniques: Transfection, Control, Western Blot, ATP Assay, Kinase Assay